3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
Whether you're looking for a way to raise the stream of passive income your portfolio produces or you simply want to outperform benchmark averages, adding some dividend-paying stocks to your portfolio ...
HealthDay on MSN2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
ascopubs.org4d
Patient characteristics and survival in primary prostate sarcomas: An analysis of the SEER database.
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ...
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
pharmaphorum1d
PARP rivals close in on AZ and Merck's market leading Lynparza
Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...
pharmaphorum6d
J&J gets restricted label for PARP drug Akeega in EU
combined with Xtandi (enzalutamide), which reported new data from the TALAPRO-2 study at ASCO GU, including a 37% reduction in rPFS in an all-comer population.
BioSpace4d
U.S. Oncology Clinical Trials Market Size to Surpass USD 12,416 Mn by 2034
For instance, in February 2023, Pfizer observed positive results from the phase III TALAPRO-2 study of talazoparib. It showcases statically prominent and clinically significant improvement in ...